BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...
Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use ...